Brokers Offer Predictions for Alnylam Pharmaceuticals, Inc.’s FY2017 Earnings (ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Stock analysts at B. Riley cut their FY2017 earnings estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Monday. B. Riley analyst M. Kumar now anticipates that the biopharmaceutical company will post earnings of ($5.32) per share for the year, down from their previous estimate of ($5.07). B. Riley has a “Buy” rating and a $205.00 price objective on the stock. B. Riley also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.60) EPS, Q2 2018 earnings at ($1.46) EPS, Q3 2018 earnings at ($1.14) EPS, Q4 2018 earnings at ($1.20) EPS and FY2018 earnings at ($4.90) EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same period last year, the company earned ($1.21) earnings per share. The business’s revenue for the quarter was up 24.8% compared to the same quarter last year.
Alnylam Pharmaceuticals (ALNY) opened at $130.74 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals has a 12 month low of $35.98 and a 12 month high of $147.63. The firm has a market cap of $12,860.00, a price-to-earnings ratio of -24.90 and a beta of 2.98.
In other news, SVP Laurie Keating sold 30,000 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the transaction, the senior vice president now directly owns 41,500 shares in the company, valued at approximately $5,639,435. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Michael Mason sold 36,745 shares of the stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the transaction, the vice president now owns 6,352 shares in the company, valued at $835,859.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 274,075 shares of company stock worth $35,356,089. 4.30% of the stock is owned by insiders.
Several hedge funds have recently made changes to their positions in ALNY. FMR LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after acquiring an additional 815,270 shares during the period. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 13.4% in the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after buying an additional 759,295 shares during the period. Janus Henderson Group PLC purchased a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $53,226,000. Orbimed Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 69.7% in the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock valued at $127,453,000 after buying an additional 445,600 shares during the period. Finally, BlackRock Inc. raised its holdings in Alnylam Pharmaceuticals by 9.3% in the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after buying an additional 441,957 shares during the period. Institutional investors and hedge funds own 88.39% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Brokers Offer Predictions for Alnylam Pharmaceuticals, Inc.’s FY2017 Earnings (ALNY)” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/10/brokers-offer-predictions-for-alnylam-pharmaceuticals-inc-s-fy2017-earnings-alny.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.